WallStreetZenWallStreetZen

NASDAQ: RGNX
Regenxbio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RGNX

Based on 8 analysts offering 12 month price targets for Regenxbio Inc

Min Forecast
$12.00-13.98%
Avg Forecast
$22.63+62.19%
Max Forecast
$50.00+258.42%

Should I buy or sell RGNX stock?

Based on 8 analysts offering ratings for Regenxbio Inc.

Strong Buy
Strong Buy
4 analysts 50%
Buy
3 analysts 37.5%
Hold
1 analysts 12.5%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RGNX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RGNX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their RGNX stock forecasts and price targets.

RGNX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-24
lockedlocked$00.00+00.00%2026-06-22
lockedlocked$00.00+00.00%2026-06-22
lockedlocked$00.00+00.00%2026-05-15
lockedlocked$00.00+00.00%2026-05-15
Morgan Stanley
Top 28%
73
Strong BuyMaintains$17.00+21.86%2026-03-06
Goldman Sachs
Bottom 7%
7
HoldMaintains$12.00-13.98%2026-02-10
Chardan Capital
Top 2%
99
Strong BuyMaintains$50.00+258.42%2026-02-10

1 of 1

Forecast return on equity

Is RGNX forecast to generate an efficient return?

Company
75.87%
Industry
90.74%
Market
171.02%
RGNX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RGNX forecast to generate an efficient return on assets?

Company
4.68%
Industry
27.39%
RGNX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RGNX earnings per share forecast

What is RGNX's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$2.80
Avg 2 year Forecast
-$2.61
Avg 3 year Forecast
-$2.16

RGNX revenue forecast

What is RGNX's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$233.5M+165.86%
Avg 2 year Forecast
$264.7M+201.43%
Avg 3 year Forecast
$357.4M+306.91%
RGNX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RGNX revenue growth forecast

How is RGNX forecast to perform vs Biotechnology companies and vs the US market?

Company
57.86%
Industry
35.38%
Market
14.17%
RGNX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RGNX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RGNX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RGNX$13.95$22.63+62.19%Strong Buy
MNPR$106.60$107.33+0.69%Strong Buy
AURA$6.84$23.00+236.26%Buy
OMER$10.28$34.50+235.60%Strong Buy
CADL$9.49$25.50+168.70%Strong Buy
View Top Biotech Stocks

Regenxbio Stock Forecast FAQ

Is Regenxbio Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: RGNX) stock is to Strong Buy RGNX stock.

Out of 8 analysts, 4 (50%) are recommending RGNX as a Strong Buy, 3 (37.5%) are recommending RGNX as a Buy, 1 (12.5%) are recommending RGNX as a Hold, 0 (0%) are recommending RGNX as a Sell, and 0 (0%) are recommending RGNX as a Strong Sell.

If you're new to stock investing, here's how to buy Regenxbio stock.

What is RGNX's earnings growth forecast for 2026-2028?

(NASDAQ: RGNX) Regenxbio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.38%.

Regenxbio's earnings in 2026 is -$290,012,000.On average, 14 Wall Street analysts forecast RGNX's earnings for 2026 to be -$144,820,546, with the lowest RGNX earnings forecast at -$248,758,613, and the highest RGNX earnings forecast at $87,394,828. On average, 13 Wall Street analysts forecast RGNX's earnings for 2027 to be -$134,677,472, with the lowest RGNX earnings forecast at -$233,052,875, and the highest RGNX earnings forecast at $63,510,527.

In 2028, RGNX is forecast to generate -$111,527,278 in earnings, with the lowest earnings forecast at -$182,895,844 and the highest earnings forecast at -$33,112,326.

What is RGNX's revenue growth forecast for 2026-2028?

(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 57.86% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.17%.

Regenxbio's revenue in 2026 is $87,822,000.On average, 14 Wall Street analysts forecast RGNX's revenue for 2026 to be $12,070,360,551, with the lowest RGNX revenue forecast at $6,840,112,235, and the highest RGNX revenue forecast at $21,115,893,297. On average, 13 Wall Street analysts forecast RGNX's revenue for 2027 to be $13,685,394,231, with the lowest RGNX revenue forecast at $3,527,225,286, and the highest RGNX revenue forecast at $25,729,905,972.

In 2028, RGNX is forecast to generate $18,474,661,841 in revenue, with the lowest revenue forecast at $9,188,735,157 and the highest revenue forecast at $32,678,066,234.

What is RGNX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RGNX) forecast ROA is 4.68%, which is lower than the forecast US Biotechnology industry average of 27.39%.

What is RGNX's Price Target?

According to 8 Wall Street analysts that have issued a 1 year RGNX price target, the average RGNX price target is $22.63, with the highest RGNX stock price forecast at $50.00 and the lowest RGNX stock price forecast at $12.00.

On average, Wall Street analysts predict that Regenxbio's share price could reach $22.63 by Jun 24, 2027. The average Regenxbio stock price prediction forecasts a potential upside of 62.19% from the current RGNX share price of $13.95.

What is RGNX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RGNX) Regenxbio's current Earnings Per Share (EPS) is -$5.60. On average, analysts forecast that RGNX's EPS will be -$2.80 for 2026, with the lowest EPS forecast at -$4.81, and the highest EPS forecast at $1.69. On average, analysts forecast that RGNX's EPS will be -$2.61 for 2027, with the lowest EPS forecast at -$4.51, and the highest EPS forecast at $1.23. In 2028, RGNX's EPS is forecast to hit -$2.16 (min: -$3.54, max: -$0.64).

What is RGNX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RGNX) forecast ROE is 75.87%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.